TGTX: BRIUMVI® Data Shows Major MS Breakthrough!

Overview – Briumvi’s MS Breakthrough and Company Background

TG Therapeutics, Inc. (NASDAQ: TGTX) is a biopharmaceutical company focused on developing and commercializing treatments for autoimmune diseases and cancers. Its lead (and currently sole marketed) product is BRIUMVI® (ublituximab-xiiy), a novel monoclonal antibody targeting a unique epitope on CD20-expressing B-cells (www.biospace.com). Briumvi was approved in late 2022 for adults with relapsing forms of multiple sclerosis (RMS) (www.nasdaq.com), making it the third anti-CD20 therapy available for MS after Roche’s Ocrevus (ocrelizumab) and Novartis’s Kesimpta (ofatumumab) (multiplesclerosisnewstoday.com). Briumvi distinguishes itself with a shorter infusion time (1-hour IV infusion every six months after an initial dosing regimen) versus Ocrevus’s 2–3.5 hour infusions (multiplesclerosisnewstoday.com). TG Therapeutics has also priced Briumvi about 20% lower than its competitors – roughly $59,000 per year vs. $75,000 for Ocrevus – giving it the lowest list price among branded MS therapies (multiplesclerosisnewstoday.com).

Recent clinical data have been widely described as a major MS breakthrough: Long-term extension results from the ULTIMATE I & II trials showed that 89.9% of patients on continuous Briumvi for 6 years had no 24-week confirmed disability progression (www.biospace.com). This durability of effect – combined with significant suppression of MRI lesions and a consistent safety profile over time – underscores Briumvi’s potential to alter the RMS treatment landscape. By 2025, surging demand for Briumvi drove TG Therapeutics’ revenues to $616 million (up 87% YoY) (www.nasdaq.com), marking the company’s transition to commercial-stage profitability. Management has characterized 2025 as a “strong year of execution,” with Briumvi achieving rapid U.S. uptake and expanding globally through partners (www.biospace.com) (www.biospace.com). Below, we dive into TGTX’s dividend stance, financial leverage, valuation, and the key risks and open questions surrounding this high-growth MS franchise.

Dividend Policy & Shareholder Returns

No Dividend History: TG Therapeutics has never declared or paid any cash dividend on its common stock (www.sec.gov). This is typical for clinical-stage and early commercial biotechs, which prioritize reinvesting cash into R&D and commercialization rather than shareholder payouts. In fact, under the covenants of its credit facility, TG is restricted from paying cash dividends for the foreseeable future (www.sec.gov). As a result, TGTX’s dividend yield is 0%, and investors seeking returns have relied entirely on stock price appreciation.

Share Buybacks: Instead of dividends, TG Therapeutics has opted to return capital to shareholders via stock repurchases, a somewhat unusual move for a company at this stage. In 2023–2025, as Briumvi’s prospects improved, the board authorized buyback programs totaling $200 million. The company completed a $100 million repurchase (3.5 million shares at ~$28.55 average price) by Q3 2025 and immediately approved another $100 million program (www.biospace.com) (www.biospace.com). Management noted this “disciplined capital allocation” reflects confidence in the long-term business outlook (www.biospace.com). These buybacks modestly reduced the share count (≈2–3% reduction) and signal that TG’s leadership views TGTX stock as undervalued. However, given growth opportunities ahead, investors will be watching whether the company continues buybacks, shifts toward debt reduction, or eventually considers dividends once cash flows mature.

Leverage and Debt Maturities

Debt Funding for Launch: To finance Briumvi’s commercial launch and pipeline work, TG Therapeutics has utilized debt strategically. In August 2024, the company entered a $250 million term loan facility with Blue Owl Capital and partners (www.sec.gov). This senior secured loan provided a single draw of $250M and an uncommitted additional $100M line (www.sec.gov). Importantly, proceeds were used to fully refinance prior debt (a Hercules Capital loan) (www.sec.gov) (www.sec.gov), extending TG’s debt maturity and lowering its cost of capital. The Blue Owl term loan carries an interest rate indexed to either a base rate or SOFR plus an applicable margin (~5.5% over SOFR initially) and matures on August 2, 2029 (www.sec.gov) (www.sec.gov). No principal repayments are due until 2028 (quarterly amortization of $12.5M begins then, unless leverage falls below a threshold) (www.sec.gov).

Current Leverage: As of year-end 2025, TG Therapeutics had $244.4 million in term loan debt outstanding (net of issuance costs) (www.sec.gov). The company held $199.5 million in cash and equivalents at that time (www.biospace.com), resulting in a modest net debt position of roughly ~$45 million. This translates to a low leverage ratio relative to 2025 EBITDA, reflecting that Briumvi’s rapid revenue ramp has begun to fund operations internally. It’s worth noting that TG’s annual interest expense is about $27 million (www.biospace.com), which is comfortably covered by operating cash flow now that Briumvi sales have scaled up. The long-dated maturity (2029) means no near-term refinancing pressure, which is advantageous as the company focuses on growth.

Debt Covenants: The term loan is secured by substantially all of TG’s assets and imposes typical restrictions – for example, limitations on additional debt, liens, M&A, and importantly any payment of dividends or stock buybacks without lender consent (www.sec.gov). (TG was able to execute its 2025 repurchases, presumably under permitted exceptions or excess cash flow conditions.) Management has stated that current cash plus projected Briumvi revenues are sufficient to fund the business plan (www.biospace.com), suggesting no additional debt or equity raise is anticipated in the near term. In summary, TGTX carries a moderate debt load with a manageable interest burden and no maturities until 2029, positioning it well to invest in its pipeline and commercialization efforts.

Coverage and Cash Flow Outlook

With Briumvi’s success, TG Therapeutics’ financial profile has improved dramatically. After years of operating losses, the company turned the corner in 2024–2025 as MS drug revenue exploded. In 2025, TG reported net income of $447.2 million (www.biospace.com), though this figure was boosted by a one-time $339.8M tax benefit from releasing a valuation allowance on deferred tax assets (i.e. recognizing past losses now expected to be usable) (www.biospace.com). Excluding that accounting benefit, pre-tax earnings were roughly $107M – still a significant improvement from near-breakeven in 2024. Notably, cash flow from operations turned positive, supported by $594M in U.S. Briumvi sales in 2025 (www.biospace.com). As a result, interest coverage (EBITDA/interest) is strong at an estimated ~8×, given ~$26.7M in 2025 interest expense (www.biospace.com) and much higher operating profit. This indicates TG can comfortably meet its debt service obligations from ongoing business cash flows.

Looking ahead, TG Therapeutics has issued robust guidance: $875–$900 million in total revenue for 2026, including $825–$850M of Briumvi U.S. sales (www.biospace.com) (www.biospace.com). If achieved, this ~45% YoY growth will further increase operating cash generation. The company plans to reinvest heavily in R&D (2026 R&D and SG&A budget of ~$350M, excluding non-cash comp) to expand Briumvi’s uses and advance new programs (www.biospace.com). Even so, at the mid-point of guidance, TGTX would likely still produce healthy free cash flow in 2026, more than sufficient to cover interest ~$25M and any deferred loan costs. AFFO/FFO metrics (common for REITs) are not applicable here; instead, investors focus on TG’s operating cash flow and earnings quality. A key point is that TG has a $199M cash cushion on the balance sheet (www.biospace.com) and expects no liquidity shortfall – “cash…combined with projected Briumvi revenues, will be sufficient to fund our business” per management (www.biospace.com). This implies the company can self-fund its growth and does not need to tap equity markets, which bodes well for shareholders (no dilution) and creditors (ample coverage). Of course, this outlook assumes Briumvi’s commercial trajectory stays on course (see Risks below).

Valuation and Comparable Metrics

Market Capitalization and Growth Premium: TGTX’s stock has re-rated sharply upward over the past two years in response to Briumvi’s approval and sales traction. As of early 2026, the share price hovers around the high-$20s (recent close ~$29), which gives TG Therapeutics a market cap of roughly $4.4–$4.8 billion. This valuation reflects a substantial growth premium: it equates to about 7.1× 2025 sales and ~5× the company’s own 2026 revenue forecast, a rich multiple in absolute terms. Traditional P/E is less meaningful at this juncture due to one-time tax effects and the company’s decision to plow earnings into R&D. For reference, TG’s reported EPS was $2.77 in 2025 (versus $0.15 in 2024) (www.nasdaq.com), but backing out the tax item, underlying EPS was closer to ~$0.65. That puts the stock at a forward P/E in the 40–50× range based on core earnings – high, but not unusual for a biotech transitioning to profitability with a long growth runway. As profitability normalizes, investors may begin to value TGTX on a PEG (price/earnings-to-growth) or discounted cash flow basis, given the multiyear expansion potential in the MS market.

Comparables: Pure-play MS biotechs are scarce, so TGTX is often compared against larger peers or the broader biotech index. For instance, Biogen and Roche (which market MS therapies like Tysabri and Ocrevus) trade at much lower sales multiples (~3–5×) due to their larger, mature portfolios. However, those pharma giants have single-digit growth and diversified risks, whereas TG is a focused high-growth story. Another benchmark: Roche’s Ocrevus generated ~CHF 4.8 billion in sales in the first 9 months of 2023 (www.roche.com) (annualizing to ~$6.5B), underscoring the enormous revenue opportunity if Briumvi captures significant share. TG’s current ~$4–5B valuation implies the market anticipates Briumvi could reach approximately $1+ billion in annual sales within a few years, but also assigns a discount for execution risks and heavy competition. It’s worth noting that despite Briumvi’s success, TGTX stock has been volatile – for example, it rallied ~30% in early 2025 (www.nasdaq.com), but then pulled back ~18% in August 2025 after an earnings miss on higher expenses (www.nasdaq.com). In the past six months (to Feb 2026) shares are up about 8%, lagging the biotech sector’s ~22% gain (www.nasdaq.com). This suggests investors are cautiously weighing TG’s torrid revenue growth against profitability and competitive dynamics. Overall, TGTX’s valuation appears to price in substantial Briumvi expansion, making continued execution key to supporting the current market cap.

Risks and Red Flags

Despite its recent achievements, TG Therapeutics faces several risks and potential red flags that investors should monitor:

– Intense Competition in MS: Briumvi is up against entrenched rivals in the MS space. Roche’s Ocrevus is a well-established standard for relapsing MS and the only approved therapy for primary progressive MS, with multi-billion sales and a decade of physician experience. Ocrevus’s manufacturer is not standing still – a new 10-minute subcutaneous (SC) injection form of Ocrevus showed non-inferiority to IV infusions in trials (www.roche.com) (www.roche.com) and could launch soon, eroding one of Briumvi’s key advantages (shorter administration). Additionally, Novartis’s Kesimpta offers the convenience of monthly at-home injections. Briumvi’s lower price and strong data have driven rapid uptake, but it must continue to prove its value to prescribers and payers amid heavyweight competition. The MS market is crowded, and larger companies could respond with aggressive pricing or next-gen products (e.g. Roche’s BTK inhibitor fenebrutinib is in Phase II/III and showed encouraging results (www.roche.com)).

– Single-Product Reliance: TG Therapeutics is currently a one-product company, deriving essentially all revenue from Briumvi (www.biospace.com) (www.biospace.com). This concentration elevates risk: any hiccup in Briumvi’s commercial trajectory – such as safety issues, new competing therapies, or changes in treatment trends – would have an outsize impact on TGTX’s financials. Furthermore, Briumvi is only approved for relapsing forms of MS; it does not have the primary progressive MS indication that expands Ocrevus’s patient pool. While TG is exploring other autoimmune uses for ublituximab (see Pipeline below), those are years away. Investors should recognize that TGTX’s fortunes are currently tied 100% to the success of Briumvi.

– Safety and Regulatory Risk: All anti-CD20 therapies carry risks like infusion reactions, infections, and rare cases of PML (brain infection) (www.biospace.com) (www.biospace.com). Briumvi’s safety profile has so far been consistent with this class and no new safety signals emerged in 6-year data (www.biospace.com). However, any unexpected adverse events could prompt stricter warnings or usage restrictions. TG Therapeutics has firsthand experience with regulatory setbacks – in 2022 it voluntarily withdrew Ukoniq (umbralisib), its previous cancer drug, from the market due to safety concerns (an increased death risk in trials) (www.sec.gov). That episode not only cut off the company’s only revenue at the time (www.sec.gov) but also raised questions about management’s oversight. While Briumvi’s outlook is far more favorable, the MS field has seen safety-driven market turbulence before (e.g. Biogen’s Tysabri was temporarily withdrawn in 2005 for PML). TG must remain vigilant in post-market surveillance and work closely with regulators to maintain Briumvi’s favorable risk-benefit profile.

– Financial and Execution Risks: Rapid growth brings execution challenges. TG Therapeutics is scaling up its commercial operations globally (Briumvi is now approved in the EU, UK, and several other regions via partner Neuraxpharm) (www.biospace.com). Managing supply chains, marketing, and medical outreach across geographies will test the relatively small company’s capabilities. There is also the risk that initial “easy” market share gains could slow – many neurologists were willing to trial Briumvi early (multiplesclerosisnewstoday.com) (multiplesclerosisnewstoday.com), but converting the broader base of physicians and patients could be harder, especially once most willing switchers have moved. On the financial side, TG has committed to high R&D spending (pursuing subcutaneous Briumvi and other programs) which could pressure margins if sales growth falters. The company’s debt, while reasonable now, could become an issue if an unexpected downturn occurred or if R&D programs fail to yield results by the late 2020s when amortization begins. In short, executing perfectly on growth while controlling costs is imperative – any slip could be punished given the stock’s growth expectations.

– Corporate Governance and Insider Activity: One subtle red flag some observers note is that CEO Michael Weiss holds both CEO and Executive Chairman roles, consolidating power. Weiss has a reputation for tenacity but also faced criticism in the Ukoniq saga for perhaps pushing ahead despite safety signals. There is no indication of malfeasance, but investors will watch governance closely. On the positive side, the recent share repurchases could be seen as alignment with shareholder interest, though they also consumed cash that might have gone to pipeline development. There haven’t been major public controversies since the 2022 drug withdrawal, but maintaining transparency and prudent decision-making will be key for management’s credibility.

Open Questions and Outlook

Going forward, several open questions surround TG Therapeutics and Briumvi’s trajectory:

– Can Briumvi Sustain Its Growth and Hit Long-Term Targets? TG Therapeutics expects ~$0.88 billion in revenue in 2026 (www.biospace.com) and presumably over $1 billion in subsequent years, which implies capturing a meaningful slice of the MS market. Investors are asking: How high can Briumvi go in a market where Ocrevus alone does ~$6+ billion annually (www.roche.com)? Will growth come mainly from switching patients off Ocrevus, from new-treatment starts, or from expanding geographies? As Briumvi penetrates earlier lines of therapy, will its efficacy edge (seen in trials) translate into real-world advantage that compels neurologists to continue adopting it widely?

– How Will Competition Evolve? The competitive landscape in MS will intensify. A critical question is how TG will fare once Roche launches Ocrevus in subcutaneous form. The SC injection could dramatically cut infusion center time, neutralizing one of Briumvi’s selling points (www.roche.com) (www.roche.com). TG is already addressing this – it has a Phase 3 program for subcutaneous ublituximab in RMS (75% enrolled as of late 2025) (www.biospace.com). But timing is uncertain; Roche’s data appear positive and could lead to an approval possibly by 2024–25, whereas TG’s own SC Briumvi won’t have topline data until end of 2026 (www.nasdaq.com). Additionally, next-generation oral therapies like BTK inhibitors are on the horizon (e.g. Roche’s fenebrutinib and Merck’s evobrutinib). If an oral drug can approach the efficacy of anti-CD20s, some patients might prefer pills over infusions. Open question: Can TG innovate fast enough – via new formulations or combination therapies – to keep Briumvi competitive in the face of these developments?

– How Robust is Briumvi’s Safety and Label Expansion Potential? Thus far, Briumvi’s safety in RMS looks in line with expectations, with no new issues in extended follow-up (www.biospace.com). However, the drug is still relatively early in its commercial life. One open question: Will any safety signals emerge with broader use (for instance, rare cases of PML or other immunosuppressive complications)? Also, will TG seek to broaden Briumvi’s label beyond RMS? The company plans a trial in a non-MS autoimmune indication in 2026 (www.biospace.com) and is already testing ublituximab in diseases like myasthenia gravis (Phase I) (www.nasdaq.com). Success there could open new markets. Conversely, these efforts could divert focus or fail to show efficacy, leaving Briumvi confined to RMS. Investors are keen to see if Briumvi can become a platform therapy across immune diseases or remain essentially an MS franchise.

– Pipeline and Diversification – What’s Next? Beyond ublituximab, TG’s pipeline is relatively thin. The most noteworthy project is azer-cel (CD19 CAR-T) for progressive MS and possibly other autoimmune diseases (www.nasdaq.com). This cell therapy approach is bold and unproven in MS – early data expected in late 2026 will be a major inflection point (www.biospace.com). Key questions: Can TG expand its portfolio to a second commercial product by the late 2020s? Will it leverage its cash flow to in-license or acquire other candidates to reduce its single-product dependence? Management has not ruled out bolt-on acquisitions, but nothing public yet. The outcome of ongoing trials (subQ Briumvi, ENHANCE dosing trial, azer-cel, etc.) will guide whether TG remains a one-product story or evolves into a multi-asset company.

– Capital Allocation – Growth vs Shareholder Returns: TG’s choice to repurchase shares in 2025 signaled confidence, but looking ahead, how will excess cash be used? If Briumvi continues to over-deliver, by 2027–2028 TG could be generating significant free cash. At that point, will the company prioritize aggressive R&D expansion (new trials, new disease areas), M&A to build the pipeline, or begin returning more cash to shareholders (via sustained buybacks or perhaps instituting a dividend)? Currently, covenants prevent a dividend (www.sec.gov) and the focus is on growth, but in the long term this could shift. Investors have an open question on what the end-game strategy is: build towards an independent diversified biotech, or drive up value for a potential acquisition by Big Pharma. Given the high strategic value of MS therapies, some speculate that if Briumvi’s trajectory stays strong, TG Therapeutics could eventually be a takeover target. Management’s actions in the next couple of years (licensing deals, partnering vs. solo commercialization overseas, etc.) will be telling in this regard.

In conclusion, TG Therapeutics’ Briumvi is making waves in the MS world with impressive efficacy data and commercial momentum – the “major MS breakthrough” moniker is backed by the 6-year disability-free outcomes seen in trials (www.biospace.com). The company’s financial footing has improved alongside its clinical success, but investors must balance the transformational upside with the very real risks of competition and concentration. TGTX offers a compelling growth story in biotech, one that will be defined by execution in the next few years. As the battle for MS patients heats up, all eyes are on TG’s ability to broaden Briumvi’s reach, advance its pipeline, and navigate the competitive responses from industry giants. The coming years will show whether this young commercial biotech can solidify its breakthrough into a durable, long-term success for patients and shareholders alike.

Sources: TG Therapeutics SEC filings and press releases; Roche financial reports; Zacks Equity Research; Multiple Sclerosis News Today (www.biospace.com) (www.sec.gov) (www.sec.gov) (www.biospace.com) (multiplesclerosisnewstoday.com) (www.roche.com) (www.sec.gov) (see inline citations for details).

For informational purposes only; not investment advice.